Skip to main content
. 2020 Apr 30;34(6):661–672. doi: 10.1007/s40263-020-00726-4

Table 4.

Summary of AEs in VPA arm (safety population)

Number of patients, n (%) Placebo (n = 4) CBD (n = 16)
At least one AE 1 (25) 14 (88)
AEs leading to discontinuation 0 (0) 2 (13)
Serious AEs 0 (0) 1 (6)
Severe AEs 0 (0) 0 (0)
Death 0 (0) 0 (0)
AEs reported by ≥ 10% of patients
 Diarrhea 0 (0) 11 (69)
 Nausea 0 (0) 2 (13)
 Nasopharyngitis 0 (0) 2 (13)

AE treatment-emergent adverse event, CBD cannabidiol, VPA valproate